Stefan Weisshaar
Overview
Explore the profile of Stefan Weisshaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fejes R, Pilat N, Lutnik M, Weisshaar S, Weijler A, Kruger K, et al.
Free Radic Biol Med
. 2024 Jul;
222:519-530.
PMID: 38972612
Background: Vascular oxidative stress and low-grade inflammation are important in the pathology of cardiovascular disorders, including hypertension. Cell culture and animal studies suggest that inorganic dietary nitrate may attenuate oxidative...
2.
Lutnik M, Weisshaar S, Mussbacher L, Steiner D, Wolzt M
Sci Rep
. 2024 Jun;
14(1):14534.
PMID: 38914694
High sugar consumption is associated with cardiovascular diseases and diabetes. Current sugar substitutes may cause taste sensations and gastrointestinal symptoms. ENSO 16 is a combination of 16 different sugar substitutes...
3.
Fejes R, Lutnik M, Weisshaar S, Pilat N, Wagner K, Stuger H, et al.
Food Funct
. 2024 Mar;
15(8):4065-4078.
PMID: 38546454
The decline in vascular function and increase in blood pressure with aging contribute to an increased cardiovascular disease risk. In this randomized placebo-controlled crossover study, we evaluated whether previously reported...
4.
Weisshaar S, Litschauer B, Reichardt B, Gruber F, Leitner S, Sibinovic S, et al.
Rheumatol Int
. 2022 May;
42(9):1597-1603.
PMID: 35589988
Patients with hyperuricemia and gout are at an increased risk for cardiovascular (CV) disease. Inhibition of the xanthine oxidase with allopurinol or febuxostat have become the mainstay for urate lowering...
5.
Weisshaar S, Brandt L, Litschauer B, Sheik-Rezaei S, Moser L, Nirnberger G, et al.
Br J Clin Pharmacol
. 2020 Mar;
86(8):1610-1619.
PMID: 32145041
Aims: Oral opioid preparations combined with naloxone are intended to induce a transient acute withdrawal syndrome to avoid intravenous misuse. This trial aimed to establish an appropriate morphine-naloxone dose ratio...
6.
Sheikh Rezaei S, Weisshaar S, Litschauer B, Gouya G, Ohrenberger G, Wolzt M
Eur J Clin Invest
. 2018 Oct;
49(1):e13041.
PMID: 30365159
Background: Increased asymmetrical dimethylarginine (ADMA) and NT pro-BNP concentrations have been associated with mortality in patients with cardiovascular (CV) disease and the general population. The use of these prognostic markers...
7.
Weisshaar S, Zeitlinger M
Drugs
. 2018 May;
78(8):799-808.
PMID: 29737499
Hypercholesterolaemia is frequently observed in patients with cardiovascular diseases (CVD) and is associated with increased mortality. Statin treatment has been the standard of care for reducing low-density lipoprotein cholesterol (LDL-C)...
8.
Weisshaar S, Litschauer B, Kerbel T, Wolzt M
Int J Cardiol
. 2017 Dec;
255:1-7.
PMID: 29288055
Background: Atorvastatin and ticagrelor have been shown to prevent against tissue injury in animals. It is unclear if these beneficial effects are also detectable in humans. We studied the effect...
9.
Weisshaar S, Litschauer B, Eipeldauer M, Hobl E, Wolzt M
Br J Clin Pharmacol
. 2017 Jul;
83(12):2651-2660.
PMID: 28715608
Aims: Animal data suggest that ticagrelor but not clopidogrel protects against tissue injury. It is unclear if this effect of ticagrelor is also detectable in humans. We studied the effect...
10.
Weisshaar S, Litschauer B, Bucher S, Riesenhuber M, Kapiotis S, Kyrle P, et al.
Medicine (Baltimore)
. 2016 Jul;
95(27):e4145.
PMID: 27399131
Background: There is a need to optimize pharmacological treatment in patients with acute coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic medicines. We have therefore studied if...